Townsend J. Adam's most recent trade in Apellis Pharmaceuticals Inc was a trade of 695 Common Stock done at an average price of $29.5 . Disclosure was reported to the exchange on Jan. 29, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 29.52 per share. | 29 Jan 2025 | 695 | 84,050 (0%) | 0% | 29.5 | 20,519 | Common Stock |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 30.43 per share. | 22 Jan 2025 | 3,323 | 84,745 (0%) | 0% | 30.4 | 101,104 | Common Stock |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 29.96 per share. | 17 Jan 2025 | 2,201 | 88,068 (0%) | 0% | 30.0 | 65,938 | Common Stock |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 28.70 per share. | 13 Jan 2025 | 2,685 | 90,269 (0%) | 0% | 28.7 | 77,065 | Common Stock |
| Apellis Pharmaceuticals Inc | Adam Townsend J. | Chief Commercial Officer | 12 Feb 2024 | 1,148 | 92,453 (0%) | 0% | 67.8 | 77,796 | Common Stock | |
| Apellis Pharmaceuticals Inc | Townsend J. Adam | Chief Commercial Officer | 29 Jan 2024 | 906 | 93,601 (0%) | 0% | 64.1 | 58,109 | Common Stock | |
| Apellis Pharmaceuticals Inc | J. Townsend Adam | Chief Commercial Officer | 22 Jan 2024 | 3,413 | 94,507 (0%) | 0% | 65.0 | 221,831 | Common Stock | |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 16 Jan 2024 | 34,533 | 34,533 | - | - | Stock Option (Right to Buy) | ||
| Apellis Pharmaceuticals Inc | Townsend J. Adam | Chief Commercial Officer | 16 Jan 2024 | 23,748 | 100,155 (0%) | 0% | 0 | Common Stock | ||
| Apellis Pharmaceuticals Inc | Townsend J. Adam | Chief Commercial Officer | 16 Jan 2024 | 2,235 | 97,920 (0%) | 0% | 66.8 | 149,317 | Common Stock | |
| Apellis Pharmaceuticals Inc | J. Townsend Adam | Chief Commercial Officer | 01 Dec 2023 | 110,000 | 186,407 (0%) | 0% | 15.1 | 1,659,900 | Common Stock | |
| Apellis Pharmaceuticals Inc | Adam Townsend J. | Chief Commercial Officer | 01 Dec 2023 | 110,000 | 172,500 | - | - | Stock Option (Right to Buy) | ||
| Apellis Pharmaceuticals Inc | J. Townsend Adam | Chief Commercial Officer | 01 Dec 2023 | 67,557 | 118,850 (0%) | 0% | 60.5 | 4,087,327 | Common Stock | |
| Apellis Pharmaceuticals Inc | J. Townsend Adam | Chief Commercial Officer | 01 Dec 2023 | 42,443 | 76,407 (0%) | 0% | 61.3 | 2,601,977 | Common Stock | |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 03 May 2023 | 5,000 | 75,995 (0%) | 0% | 82.7 | 413,550 | Common Stock | |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 03 May 2023 | 5,000 | 80,995 (0%) | 0% | 15.1 | 75,450 | Common Stock | |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 03 May 2023 | 5,000 | 282,500 | - | - | Stock Option (Right to Buy) | ||
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 03 Apr 2023 | 5,000 | 287,500 | - | - | Stock Option (Right to Buy) | ||
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 03 Apr 2023 | 5,000 | 75,995 (0%) | 0% | 74.1 | 370,250 | Common Stock | |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 03 Apr 2023 | 5,000 | 80,995 (0%) | 0% | 15.1 | 75,450 | Common Stock | |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 03 Mar 2023 | 5,000 | 75,995 (0%) | 0% | 63.8 | 319,200 | Common Stock | |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 03 Mar 2023 | 5,000 | 80,995 (0%) | 0% | 15.1 | 75,450 | Common Stock | |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 03 Mar 2023 | 5,000 | 292,500 | - | - | Stock Option (Right to Buy) | ||
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 21 Feb 2023 | 14,023 | 14,023 | - | - | Stock Option (Right to Buy) | ||
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 21 Feb 2023 | 9,886 | 77,036 (0%) | 0% | 0 | Common Stock | ||
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 21 Feb 2023 | 1,041 | 75,995 (0%) | 0% | 58.5 | 60,899 | Common Stock | |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 10 Feb 2023 | 782 | 67,150 (0%) | 0% | 51.2 | 40,046 | Common Stock | |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 03 Feb 2023 | 5,000 | 67,932 (0%) | 0% | 55.9 | 279,250 | Common Stock | |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 03 Feb 2023 | 5,000 | 297,500 | - | - | Stock Option (Right to Buy) | ||
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 03 Feb 2023 | 5,000 | 72,932 (0%) | 0% | 15.1 | 75,450 | Common Stock | |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 27 Jan 2023 | 551 | 67,932 (0%) | 0% | 52.8 | 29,076 | Common Stock | |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 20 Jan 2023 | 1,912 | 68,483 (0%) | 0% | 52.1 | 99,520 | Common Stock | |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 12 Jan 2023 | 43,183 | 43,183 | - | - | Stock Option (Right to Buy) | ||
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 12 Jan 2023 | 27,488 | 70,395 (0%) | 0% | 0 | Common Stock | ||
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 03 Jan 2023 | 5,000 | 302,500 | - | - | Stock Option (Right to Buy) | ||
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 03 Jan 2023 | 5,000 | 42,907 (0%) | 0% | 50.7 | 253,500 | Common Stock | |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 03 Jan 2023 | 5,000 | 47,907 (0%) | 0% | 15.1 | 75,450 | Common Stock | |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 05 Dec 2022 | 5,000 | 47,907 (0%) | 0% | 15.1 | 75,450 | Common Stock | |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 05 Dec 2022 | 5,000 | 307,500 | - | - | Stock Option (Right to Buy) | ||
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 05 Dec 2022 | 5,000 | 42,907 (0%) | 0% | 50.4 | 251,900 | Common Stock | |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 03 Nov 2022 | 5,000 | 47,907 (0%) | 0% | 15.1 | 75,450 | Common Stock | |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 03 Nov 2022 | 5,000 | 312,500 | - | - | Stock Option (Right to Buy) | ||
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 03 Nov 2022 | 5,000 | 42,907 (0%) | 0% | 58.5 | 292,700 | Common Stock | |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 03 Oct 2022 | 5,000 | 317,500 | - | - | Stock Option (Right to Buy) | ||
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 03 Oct 2022 | 5,000 | 42,907 (0%) | 0% | 66.7 | 333,450 | Common Stock | |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 03 Oct 2022 | 5,000 | 47,907 (0%) | 0% | 15.1 | 75,450 | Common Stock | |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 06 Sep 2022 | 5,000 | 42,907 (0%) | 0% | 60.4 | 301,900 | Common Stock | |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 06 Sep 2022 | 5,000 | 322,500 | - | - | Stock Option (Right to Buy) | ||
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 06 Sep 2022 | 5,000 | 47,907 (0%) | 0% | 15.1 | 75,450 | Common Stock | |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 15 Aug 2022 | 12,500 | 327,500 | - | - | Stock Option (Right to Buy) | ||
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 15 Aug 2022 | 12,500 | 42,907 (0%) | 0% | 69 | 862,500 | Common Stock | |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 15 Aug 2022 | 12,500 | 55,407 (0%) | 0% | 15.1 | 188,625 | Common Stock | |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 11 Aug 2022 | 12,500 | 55,407 (0%) | 0% | 15.1 | 188,625 | Common Stock | |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 11 Aug 2022 | 12,500 | 340,000 | - | - | Stock Option (Right to Buy) | ||
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 11 Aug 2022 | 12,500 | 42,907 (0%) | 0% | 67 | 837,500 | Common Stock | |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 08 Aug 2022 | 12,500 | 55,407 (0%) | 0% | 15.1 | 188,625 | Common Stock | |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 08 Aug 2022 | 12,500 | 352,500 | - | - | Stock Option (Right to Buy) | ||
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 08 Aug 2022 | 12,500 | 42,907 (0%) | 0% | 65 | 812,500 | Common Stock | |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 03 Aug 2022 | 5,000 | 37,907 (0%) | 0% | 56.4 | 282,150 | Common Stock | |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 03 Aug 2022 | 5,000 | 365,000 | - | - | Stock Option (Right to Buy) | ||
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 03 Aug 2022 | 5,000 | 42,907 (0%) | 0% | 15.1 | 75,450 | Common Stock | |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 21 Apr 2022 | 11,250 | 0 | - | - | Stock Option (Right to Buy) | ||
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 21 Apr 2022 | 5,000 | 47,907 (0%) | 0% | 15.1 | 75,450 | Common Stock | |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 21 Apr 2022 | 5,000 | 370,000 | - | - | Stock Option (Right to Buy) | ||
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 21 Apr 2022 | 5,000 | 42,907 (0%) | 0% | 48.4 | 242,100 | Common Stock | |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 21 Apr 2022 | 1,875 | 42,138 (0%) | 0% | 0 | Common Stock | ||
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 10 Feb 2022 | 895 | 44,013 (0%) | 0% | 47.1 | 42,172 | Common Stock | |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 28 Jan 2022 | 800 | 44,908 (0%) | 0% | 38.6 | 30,872 | Common Stock | |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 21 Jan 2022 | 36,951 | 36,951 | - | - | Stock Option (Right to Buy) | ||
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 21 Jan 2022 | 26,051 | 45,708 (0%) | 0% | 0 | Common Stock | ||
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 10 Feb 2021 | 688 | 18,865 (0%) | 0% | 47.7 | 32,831 | Common Stock | |
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 28 Jan 2021 | 45,000 | 45,000 | - | - | Stock Option (Right to Buy) | ||
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 28 Jan 2021 | 11,250 | 11,250 | - | - | Stock Option (Right to Buy) | ||
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 28 Jan 2021 | 7,500 | 17,678 (0%) | 0% | 0 | Common Stock | ||
| Apellis Pharmaceuticals Inc | Adam J. Townsend | Chief Commercial Officer | 28 Jan 2021 | 1,875 | 19,553 (0%) | 0% | 0 | Common Stock |